BY Health & Biotech | Nadine McGrath Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to EZZ Life Science (ASX:EZZ) Chief Strategy Officer Glenn Cross. He discusses the company’s expanding health and wellness business across Australia and international markets. He …
Read more “Vital Signs Podcast: EZZ targets Global Wellness Growth”
BY Health & Biotech | Tim Boreham • The health and wellness products purveyor has suffered from cheap Chinese knockoffs• The company has emphasised the Australian market while targeting other Asian geographies• After “disappointing” annual results, management is striving to diversify the company’s sales channel and invest in product innovation As a purveyor of health …
Read more “Biocurious: EZZ looks to return serve against Chinese knockoffs”
BY Health & Biotech | Nadine McGrath • EZZ is reducing its reliance on Chinese e-commerce as it expands pharmacy distribution• Bubs is building the US while keeping China central to its growth plans• Vita Life is refining its China strategy as other Asian markets grow Cracking the Chinese market has long been the growth …
Read more “ASX health and wellness brands look beyond China for diversified growth”
BY Special Report Special Report: In a major distribution boost, EZZ Life Science’s newly launched MeTime range is being sold via Woolworths Group’s (ASX:WOW) HealthyLife platform, with additional reach across its broader supermarket online retail ecosystem. EZZ Life Science (ASX:EZZ) launched MeTime for the Australian Market in May with the range designed to support everyday …
BY Special Report Research co-funded by EZZ suggests that three healthy ageing compounds – including NMN – work well in combination University of Auckland research published in the peer-reviewed journal Redox Biology EZZ pursuing research partnerships with academia to develop health and wellness products backed by scientific validation Special Report: Co-funded by EZZ Life Science, …
Read more “EZZ-backed research highlights compound’s role in healthy ageing”
BY Nadine McGrath Genuine Aussie-made products may benefit as China cracks down on falsely marketed imports. Pic: Getty Images China’s reported crackdown on falsely marketed imported supplements could favour ASX healthcare companies with verified Australian-made products Xenitra delivers high-quality FMCG, nutraceuticals and over-the-counter (OTC) medicine products from Australia and New Zealand into Asia Bubs Australia …
Read more “Made in Australia: ASX healthcare plays tipped to gain from China crackdown”
BY Special Report Morosil, a patented Bionap extract standardised from Moro blood oranges, is featured in the MeTime range. Pic: Getty Images EZZ launches MeTime functional wellness range for Australian market Enters ingredient partnership with Italian botanical extract specialist Bionap Partnership reflects company’s commitment to clinically supported, professionally standardised ingredient Special Report: EZZ Life Science …
Read more “EZZ launches MeTime wellness range, enters partnership with Italian firm Bionap”
BY Nadine McGrath Manufacturing in the US offers ASX companies resilience to tariffs and proximity to customers Eden Innovations traces its origins to the US and has a strong manufacturing footprint in the country AML3D has also been expanding its US footprint to meet demand from growing defence contracts For years, Australian companies chasing …
Read more “Made in America: ASX companies manufacturing inside Trump’s tariff wall”
BY Special Report EZZ is tapping JD Health’s platform to power its next phase of China growth. Pic: Getty Images. EZZ expands China growth strategy with JD Health Platform strategic cooperation framework JD Health operates one of China’s largest online healthcare ecosystems Framework will see EZZ tap into JD Health’s large user base, integrated …
Read more “EZZ flexes China growth strategy with JD Health deal”
BY Special Report EZZ is joining with Aumake for global distribution of co-developed EZZ-branded products. Pic: Getty Images. EZZ enters four-year global distribution deal with Aumake for co-developed EZZ-branded products Includes minimum purchase commitments of $10 million over term of agreement and $2.5 million annual purchases Aumake appointed as exclusive global distributor across …
Read more “EZZ inks global distribution deal with Aumake for co-developed products”
Director of Corporate Affairs, EZZ Life Science Holdings
James Hudson is the Director of Corporate Affairs at EZZ Life Science, where he oversees media relations, investor relations, and public affairs for the company.
Before joining EZZ, James was the Director of Corporate Affairs and Marketing at Alibaba Group for Australia and New Zealand. He has also served as the CEO of the Australia China Business Council's NSW branch, where he supported member companies in trade, investment, and business engagements with China. Additionally, he has held the role of China and East Asia Adviser at CSIRO, Australia’s national science research agency.
James has been appointed to various Advisory Board and Ambassador positions, including with the Asia Education Foundation, the China Australia Millennial Project, AsiaRecon, the Asian Football Cup, and Austrade’s Approved Destination Status Advisory Panel. He has also served as a non-executive director for organisations such as OneSky Australia and the Castlemaine State Festival.
Company Secretary
Jay Stephenson has been involved in business development for over 35 years including approximately 29 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities in resources, manufacturing, information technology, health care, wine, hotels and property. Jay has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.
Jay provides services in IPO/RTO management, Corporate Advisory, Company Administration, Accounting and Corporate Governance. On most engagements, Jay takes on the appointment of a statutory office holder, either as a Director, Company Secretary or Chief Financial Officer.
Jay holds a Master of Business Administration, is a Chartered Accountant, Fellow of Certified Practicing Accountants Australia, A Fellow of the Governance Institute of Australia, a member of Chartered Professional Accountants and Certified Management Accountants in Canada.
Chief Financial Officer
With over 30 years of experience as a chartered accountant, Anthony Guarna has held positions at Deloitte, BDO, and Nexia, both domestically and internationally. He has provided financial leadership at organizations such as Energy Australia, the University of Sydney, Macquarie University, Tower Life, Electroboard Group, the Australian Institute of Higher Education, Austral Gold Limited (ASX: AGD), Aumake Limited (ASX: AUK), and Freedom Insurance Group Limited (ASX: FIG). Anthony also serves as a Non-Executive Director of the Sydney Institute of Traditional Chinese Medicine and is a member of the Advisory Board at Medigalaxy.
Independent Non-Executive Director
With more than 20 years in senior management within the banking industry, Lily Huang serves as Vice President in the investment partnerships division at Citi Group Australia. Her leadership was recognized in 2015 when she was named among the Top 10 Australian Chinese Entrepreneurs.
Independent Non-Executive Director
Bringing over 30 years of legal practice experience both in Australia and internationally, Ivan Oshry specializes in corporate law. He has advised on numerous IPO transactions globally and is a sought-after speaker at various conferences, reflecting his deep industry knowledge.
Executive Director and Chief Executive Officer
An award-winning research analyst and accomplished entrepreneur, Mark Qin co-founded CE International, a multi-award-winning marketing consulting firm. Between 2003 and 2008, he authored five books on sales and marketing within the healthcare industry, showcasing his dedication to advancing the sector.
Independent Non-Executive Director and Chairman
With four decades in the life sciences sector, Glenn Cross has held senior executive roles across multinational and Australian companies. His expertise spans general management, sales, marketing, finance, distribution, and manufacturing. Notably, Glenn served as Chief Operating Officer and CEO of AusBiotech for over 13 years. Currently, he contributes as a non-executive director to various private and public companies, as well as investment funds.